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CytotoxicityAbstract The development of new antitumor agents is one of the most pressing research areas in
medicinal chemistry and medicine. The importance of triazole and thiadiazole rings as scaffolds pre-
sent in a wide range of therapeutic agents has been well reported and has driven the synthesis of a
large number of novel antitumor agents. The presence of these heterocycles furnishes extensive syn-
thetic possibilities due to the presence of several reaction sites. Prompted by these data we designed,
synthesized and evaluated a series of novel 3,6-disubstituted 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole
derivatives as potential anticancer agents. We emphasized in the strategy of combining two chem-
ically different but pharmacologically compatible molecules (the 1,2,4-triazole and 1,3,4 thiadia-
zole) in one frame. Several of the newly synthesized 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole
derivatives showed substantial cytostatic and cytotoxic antineoplastic activity invitro, while they
have produced relatively low acute toxicities invivo, giving potentially high therapeutic ratios. Insil-
ico screening has revealed several protein targets including apoptotic protease-activating factor 1@eie.gr,
ivatives.
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Arabian Journal of Chemistry (2016), http:/(APAF1) and tyrosine-protein kinase HCK which may be involved in the biological activities of
active analogues.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cancer is among the leading causes of morbidity and mortality world-
wide and remains a major public health issue at the beginning of the
21st century. Approximately 14 million new cases and 8.2 million can-
cer related deaths were reported in 2012. More than 60% of global new
annual cases occur in Africa, Asia and Central and South America.
These developing and under-developed regions account for 70% of
the world’s cancer deaths. The number of new cases is expected to rise
by about 70% over the next 2 decades (World Cancer Report, 2014).
The successful treatment of cancer remains a significant challenge
because of the general toxicity associated with the clinical use of tradi-
tional cancer chemotherapeutic agents. Significant side effects such as
nausea, vomiting, diarrhea, hair loss and serious infections (mostly due
to leukopenia) often accompany chemotherapy. Therefore, the need
for accelerated development of new, more effective as well as less toxic
chemotherapeutic agents is unquestioned. The development of new
antitumor agents is one of the most urgent research areas in medicinal
chemistry and oncology.
The importance of triazole or thiadiazole rings as scaffolds present
in a range of therapeutic agents, which furnish extensive synthetic pos-
sibilities due to the presence of several reaction sites, has driven the
synthesis of a large number of novel antitumor agents bearing these
heterocycles. Thiadiazoles have been of great interest as core structures
of antitumor agents for many years (Hill, 1980; Nelson et al., 1977;
Tsukamoto et al., 1975), possibly due to the presence of toxophoric
N-C-S moiety (Omar and Aboulwafa, 1986). Also, the triazole ring
is highly reactive, due to the presence of an acidic proton at C-2,
and emerges as an important synthon to generate new chemical enti-
ties. Diverse modifications of the triazole or thiadiazole rings at vari-
ous positions have led to a variety of novel compounds with wide
spectrum of pharmacological activities.
As a result of the above findings, several patents were registered
from 2008 to present concerning new triazole and thiadiazole ring con-
taining derivatives useful for the development of new anticancer drug
molecules (Morigi et al., 2015).
Therefore, the fused compounds and their derivatives obtained by
fusing the bio-labile 1,2,4-triazole and 1,3,4-thiadiazole rings together
represent an interesting class of heterocyclic compounds with a broad
spectrum of pharmacological activities which include antifungal
(Chaturvedi et al., 1988; Karabasanagouda et al., 2007), antibacterial
(Demirbas et al., 2005; Holla et al., 1996; Zhang et al., 1997), antiviral
(Invidiata et al., 1996; Kritsanida et al., 2002; Srivastava et al., 1994),
anti-inflammatory (Amir et al., 2008; Chawla et al., 2012; Prasad et al.,
1986), analgesic (Chawla et al., 2012; Srivastava et al., 1994), and
anthelmintic (El-Khawass et al., 1989; Hussain and Kumar, 1992)
while of particular interest is the impressive anticancer/antitumor
activity (Al-Masoudi and Al-Soud, 2008; Chowrasia et al., 2013;
Ibrahim, 2009; Kaliappan and Parthiban, 2010). More specifically,
the cytotoxic potency of 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles against
various cancer cell lines has been extensively reported (Husain et al.,
2013; Shivarama Holla et al., 2002; Subrahmanya Bhat et al., 2004;
Sunil et al., 2010).
Prompted by these observations and in continuation of our search
for alternate chemotherapeutic compounds, we synthesized and evalu-
ated a series of novel 3,6-disubstituted 1,2,4-triazolo-[3,4-b]-1,3,4-thia
diazole derivatives as potential anticancer agents. In particular, we
emphasized the strategy of combining two chemically different but
pharmacologically compatible molecules (the 1,2,4-triazole and 1,3,4
thiadiazole) in one frame.. et al., Synthesis and anticancer activ
/dx.doi.org/10.1016/j.arabjc.2016.09.015A simple sulfonamide may play the role of the initial lead com-
pound for the synthesis of the target triazolo thiadiazoles. In general,
a novel series of sulfonamide derivatives containing different, biologi-
cally active, moieties including pyridine, thiophene or benzothiophene
moieties have also shown promising anticancer activity. The chemical
motif of aromatic/heterocyclic sulfonamide has been correlated with a
variety of antitumor mechanisms, such as carbonic anhydrase inhibi-
tion, cell cycle arrest in the G1 phase, disruption of microtubule assem-
bly, functional suppression of the transcriptional activator NF-Y, and
angiogenesis (matrix metalloproteinase, MMP) inhibition among
others (Ghorab et al., 2015).
2. Materials and methods
2.1. Chemistry
The 2-(N,N-dimethylsulfamoyl)-4,5-dimethoxy-phenylacetyla
cetylhydrazide (I), prepared from ethyl-2-(N,N-dimethylsulfa
moyl)-4,5-dimethoxy-phenylacetate by treatment with hydra-
zine hydrate in xylol (Ezabadi et al., 2008), was allowed to react
with carbon disulfide in the presence of potassium hydroxide in
ethanol to afford the corresponding intermediate potassium
thiocarbamate (II). This salt underwent ring closure with excess
of hydrazine hydrate to give 5-[2-(N,N-dimethylsulfamoyl)-4,5-
dimethoxybenzyl]-3-mercapto-4-amino-1,2,4-triazole (III). The
resulted triazole was further converted to 3,6-disubstituted 1,
2,4-triazolo[3,4-b]-1,2,4-thiadiazoles (IV) by condensing with
various aromatic acids in the presence of phosphorus
oxychloride as outlined in Scheme 1 and Table 1.
2.1.1. 5-[2-(N,N-dimethylsulfamoyl)-4,5-dimethoxy-benzyl]-4-
amino-3-mercapto-1,2,4-triazole (III)
To a cold stirred solution of 2-(N,N-dimethylsulfamoyl)-4,5-
dimethoxy-phenylacetyl hydrazide (0.01 mol) in absolute
ethanol (150 mL) containing potassium hydroxide
(0.015 mol), carbon disulfide (0.015 mol) was added gradually.
The reaction mixture was stirred at room temperature for 20 h
where upon a precipitate of the corresponding potassium
dithiocarbamate was separated. Dry ether (150 mL) was then
added to complete the precipitation of the formed salt. The
obtaining product was filtered, washed with dry ether and
dried.
The above salt was suspended in 80% hydrazine hydrate
(0.02 mol), stirred and heated under reflux for 2 h. The
reaction mixture was cooled, diluted with ice cold water and
neutralized with 10% hydrochloric acid. The precipitate
obtained, was filtered, washed thoroughly with cold water,
dried and recrystallized from methanol.
Yield: 56%, M.p. 194–196 C (CH3OH). I.R. v cm1 3314,
3250 (NH), 2942 (CH), 1604 (C‚N), 1574, 1510, 1448 (C‚C),
1265 (NAN‚C), 1326 (SAO anti sym), 1135 (SAO sym).
1H NMR d (ppm): 13.39 (s, 1H, SH), 7.25 (s, 1H, ArH),
7.02 (s, 1H, ArH), 5.56 (s, 2H, NH2), 4.30 (s, 2H, CH2),
3.79 (s, 6H, 2CH3AOA), 2.59 (s, 6H, N(CH3)2).ity of novel 3,6-disubstituted 1,2,4-triazolo-[3,4-b]-1,3, 4-thiadiazole derivatives.
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Scheme 1 Synthetic route for the newly synthesized analogues.
Table 1 The 20 novel triazolo-thiadiazole analogues.
Analogue Substituent Analogue Substituent
IVa C6H5A IVk 4ACH3OAC6H4CH2A
IVb 4-ClAC6H4A IVl 3,4-CH3OAC6H3CH2A
IVc 2-NH2AC6H4A IVm C6H5AOCH2A
IVd 3-NH2AC6H4A IVn C6H5ACH‚CH
IVe 4-NH2AC6H4A IVo 2-CH3OAC6H4CH2CH2A
IVf 2-ClA4-NO2AC6H3A IVp 4-CH3OAC6H4CH2CH2A
IVg 3-CH3A4-NO2AC6H3A IVq C6H5CH2CH2 CH2A
IVh 3,4,5-CH3OAC6H2A IVr
N
R
IVi C6H5CH2A IVs NR
IVj 3-CH3OAC6H4CH2A IVt
N
R
Br
Synthesis and anticancer activity 3Analysis: C13H19N5O4S2 (373). Calc.%: C:41.82, H:5.09,
N:18.76. Found: C:41.77, H:5.12, N:18.79.2.1.2. General procedure for the synthesis of 3,6-disubstituted-
1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazoles (IVa–t)
An equimolar mixture of triazole (III) (0.01 mol) and appro-
priate aromatic acids (0.01 mol) in dry phosphorus oxychlo-
ride (5 mL) was refluxed for 2 h. The reaction mixture was
cooled to room temperature and then gradually poured onto
crushed ice with stirring. Finally, to remove the excess of phos-
phorus oxychloride, powdered potassium carbonate and the
required amount of solid potassium hydroxide were added till
the pH of the mixture was raised to 8. The solid was collectedPlease cite this article in press as: Charitos, G. et al., Synthesis and anticancer activi
Arabian Journal of Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.09.015by filtration, washed thoroughly with cold water, dried and
recrystallized from the appropriate solvent.
The following compounds were prepared by an analogous
procedure.
2.1.2.1. 3-[2-(N,N-dimethylsulfamoyl)-4,5-dimethoxy-benzyl]-
6-phenyl-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (IVa). Yield:
74%, M.p. 212–214 C (CH3OH), 1H NMR (CDCl3) d 7.95
(d, J= 6.9 Hz, 2H), 7.68 (m, 1H), 7.63 (m, 2H), 7.30
(s, 1H), 7.21 (s, 1H), 4.78 (s, 2H), 3.84 (s, 3H), 3.80 (s, 3H),
2.63 (s, 6H), I.R. v cm1 1601 (C‚N), 1573, 1513, 1470,
1446 (C‚C), 1265 (NAN‚C), 1328 (SAO antisym.), 1141
(SAO sym.), Analysis: C20H21N5O4S2 (459). Calc.%:
C:52.28, H:4.57, N:15.25. Found: C:52.25, H:4.53, N:15.27.ty of novel 3,6-disubstituted 1,2,4-triazolo-[3,4-b]-1,3, 4-thiadiazole derivatives.
4 G. Charitos et al.2.1.2.2. 3-[2-(N,N-dimethylsulfamoyl)-4,5-dimethoxy-benzyl]-
6-(4-chloro-phenyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole
(IVb). M.p. 228–229 C (CH3OHACH2Cl2), 1H NMR
(CDCl3) d 7.97 (d, J= 8.5 Hz, 2H), 7.71 (d, J= 8.6 Hz,
2H), 7.30 (s, 1H), 7.20 (s, 1H), 4.78 (s, 2H), 3.84 (s, 3H),
3.79 (s, 3H), 2.62 (s, 6H), I.R. v cm1 1600(C‚N), 1573,
1519, 1470 (C‚C), 1272 (NAN‚C), 1339(SAO antisym.),
1138 (SAO sym), Analysis: C20H20N5O4S2Cl (493.5). Calc.
%: C:48.63, H:4.05, N:14.18. Found: C:48.65, H:4.01, N:14.21.
2.1.2.3. 3-[2-(N,N-dimethylsulfamoyl)-4,5-dimethoxy-benzyl]-
6-(2-amino-phenyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole
(IVc). Yield: 36%. M.p. 219–220 C (C2H5OH), 1H NMR
(CDCl3) d 7.30 (s, 1H), 7.23 (t, J= 7.8 Hz, 1H), 7.20 (s,
1H),7.13 (m, 1H), 7.03 (d, J= 8.35 Hz, 1H), 6.82 (d,
J= 8.2 Hz, 1H), 4.75 (s, 2H), 3.84 (s, 3H), 3.79 (s, 3H), 2.61
(s, 6H), I.R. v cm1 2436, 3382, 3267 (NAH), 1608 (C‚N),
1555, 1514, 1474 (C‚C), 1265 (NAN‚C), 1328 (SAO anti-
sym.), 1141 (SAO sym.), Analysis: C20H22N6O4S2 (474).
Calc.%: C:50.63, H:4.64, N:17.72. Found: C:50.60, H:4.61,
N:17.75.
2.1.2.4. 3-[2-(N,N-dimethylsulfamoyl)-4,5-dimethoxy-benzyl]-
6-(3-amino-phenyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole
(IVd). Yield: 20%. M.p. 164–165 C (C2H5OH), 1H NMR
(CDCl3) d 7.44 (dd, J= 8.0, 1.4 Hz, 1H), 7.29 (m, 1H), 7.28
(s, 1H), 7.16 (s, 1H), 6.93 (d, J= 8.4 Hz, 1H), 6.71 (bs, 2H,
NH2), 6.68 (t, J= 7.5 Hz, 1H), 4.81 (s, 2H), 3.84 (s, 3H),
3.78 (s, 3H), 2.63 (s, 6H), I.R. v cm1, 3450, 3347 (NAH),
1626 (C‚N), 1579, 1512, 1473 (C‚C), 1272 (NAN‚C),
1322 (SAO antisym.), 1129 (SAO sym.), Analysis: C20H26N6-
O4S2 (474). Calc.%: C:50.63, H:4.64, N:17.72. Found:
C:50.65, H:4.67, N:17.69.
2.1.2.5. 3-[2-(N,N-dimethylsulfamoyl)-4,5-dimethoxy-benzyl]-
6-(4-amino-phenyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole
(IVe). Yield: 18%. M.p. 179–181 C (C2H5OH), 1H NMR
(CDCl3) d 7.58 (dd, J= 8.6, 2.9 Hz, 2H), 7.29 (d,
J= 3.0 Hz, 1H), 7.19 (d, J= 2.8 Hz, 1H), 6.68 (dd, J= 8.6,
2.9 Hz, 2H), 6.17 (s, 2H), 4.72 (s, 2H), 3.84 (s, 3H), 3.78 (s,
3H), 2.61 (s, 6H), I.R. v cm1 3457, 3348, 3237 (NAH), 1603
(C‚N), 1577, 1518, 1461 (C‚C), 1265 (NAN‚C), 1331
(SAO antisym.), 1138 (SAO sym.), Analysis: C20H26N6O4S2
(474). Calc.%: C:50.63, H:4.64, N:17.72. Found: C:50.60,
H:4.59, N:17.70.
2.1.2.6. 3-[2-(N,N-dimethylsulfamoyl)-4,5-dimethoxy-benzyl]-
6-(2-chloro-4-nitro-phenyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadia-
zole (IVf). Yield: 65%. M.p. 216–217 C (CH3OH), 1H NMR
(CDCl3) d 8.57 (d, J= 2.3 Hz, 1H), 8.40 (dd, J= 8.7, 2.3 Hz,
1H), 8.27 (d, J= 8.7 Hz, 1H), 7.30 (s, 1H), 7.20 (s, 1H), 4.80
(s, 2H), 3.84 (s, 3H), 3.80 (s, 3H), 2.61 (s, 6H), I.R. v cm1
1603(C‚N), 1573, 1518, 1476 (C‚C), 1269 (NAN‚C),
1331 (SAO antisym.), 1138 (SAO sym.), Analysis: C20H19N6-
O6S2Cl (538.5). Calc.%: C:44.56, H:3.52, N:15.60. Found:
C:44.53, H:3.55, N:15.63.
2.1.2.7. 3-[2-(N,N-dimethylsulfamoyl)-4,5-dimethoxy-benzyl]-
6-(3-methyl-4-nitro-phenyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadia-
zole (IVg). Yield: 46%. M.p. 142–144 C (CH3OH), 1H NMR
(CDCl3) d 8.18 (d, J= 8.5 Hz, 1H), 8.08 (s, 1H), 8.02 (d,Please cite this article in press as: Charitos, G. et al., Synthesis and anticancer activ
Arabian Journal of Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.09.015J= 8.5 Hz, 1H), 7.30 (s, 1H), 7.22 (s, 1H), 4.80 (s, 2H), 3.84
(s, 3H), 3.80 (s, 3H), 2.62 (s, 6H), I.R. v cm1 1600(C‚N),
1573, 1510, 1476 (C‚C), 1271 (NAN‚C), 1344 (SAO anti-
sym.), 1133 (SAO sym.), Analysis: C21H22N6O6S2 (518).
Calc.%: C:48.64, H:4.24, N:16.21. Found: C:48.68, H:4.21,
N:16.25.
2.1.2.8. 3-[2-(N,N-dimethylsulfamoyl)-4,5-dimethoxy-benzyl]-
6-(3,4,5-trimethoxy-phenyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadi-
azole (IVh). Yield: 38%. M.p. 169–170 C (CH3OH),1H
NMR (CDCl3) d 7.30 (s, 1H), 7.22 (s, 1H), 7.14 (s, 2H), 4.78
(s, 2H), 3.89 (s, 6H), 3.84 (s, 3H), 3.80 (s, 3H), 3.76 (s, 3H),
2.62 (s, 6H), I.R. v cm1 1630(C‚N), 1586, 1459, 1414
(C‚C), 1267 (NAN‚C), 1333 (SAO antisym.), 1127 (SAO
sym.), Analysis: C23H27N5O7S2 (549). Calc.%: C:50.27,
H:4.92, N:12.75. Found: C:50.25, H:4.96, N:12.78.
2.1.2.9. 3-[2-(N,N-dimethylsulfamoyl)-4,5-dimethoxy-benzyl]-
6-benzyl-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (IVi). Yield:
18%. M.p. 178–179 C (CH3OH); 1H NMR (CDCl3) d 7.42–
7.36 (m, 4H), 7.36–7.30 (m, 1H), 7.28 (s, 1H), 7.13 (s, 1H),
4.69 (s, 2H), 4.44, (s, 2H), 3.84 (s, 3H), 3.76 (s, 3H), 2.57 (s,
6H), I.R. v cm1 1601 (C‚N), 1565, 1517, 1475 (C‚C),
1267 (NAN‚C), 1339 (SAO antisym.), 1140 (SAO sym.),
Analysis: C21H23N5O4S2 (473). Calc.%: C:53.27, H:4.86,
N:14.80. Found: C:53.23, H:4.89, N:14.83.
2.1.2.10. 3-[2-(N,N-dimethylsulfamoyl)-4,5-dimethoxy-ben-
zyl]-6-(3-methoxy-benzyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadia-
zole (IVj). Yield: 58%. M.p. 165–166 C (CH3OH), 1H NMR
(CDCl3) d 7.30 (d, J= 8.0 Hz, 1H), 7.29 (s, 1H), 7.13 (s, 1H),
6.97 (s, 1H), 6.94 (d, J= 7.7 Hz, 1H), 6.90 (dd, J= 8.3,
2.5 Hz, 1H), 4.70 (s, 2H), 4.41 (s, 2H), 3.84 (s, 3H), 3.77 (s,
3H), 3.75 (s, 3H), 2.57 (s, 6H), I.R. v cm1 1607 (C‚N),
1581, 1515, 1491 (C‚C), 1266 (NAN‚C), 1334 (SAO anti-
sym.), 1139 (SAO sym.), Analysis: C22H25N5O5S2 (503).
Calc.%: C:52.48, H:4.97, N:13.91. Found: C:52.44, H:4.95,
N:12.88.
2.1.2.11. 3-[2-(N,N-dimethylsulfamoyl)-4,5-dimethoxy-ben-
zyl]-6-(4-methoxy-benzyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadia-
zole (IVk). Yield: 52%. M.p. 184–185 C (CH3OH), 1H NMR
(CDCl3) d 7.30 (d, J= 8.6 Hz, 2H), 7.29 (s, 1H), 7.13 (s, 1H),
6.94 (d, J= 8.6 Hz, 2H), 4.69 (s, 2H), 4.36 (s, 2H), 3.84 (s,
3H), 3.77 (s, 3H), 3.75 (s, 3H), 2.57 (s, 6H), I.R. v cm1 1610
(C‚N), 1571, 1514, 1476 (C‚C), 1267 (NAN‚C), 1340
(SAO antisym.), 1140 (SAO sym.), Analysis: C22H25N5O5S2
(503). Calc.%: C:52.48, H:4.97, N:13.91. Found: C:52.45,
H:4.99, N:13.94.
2.1.2.12. 3-[2-(N,N-dimethylsulfamoyl)-4,5-dimethoxy-ben-
zyl]-6-(3,4-dimethoxy-benzyl)-1,2,4-triazolo[3,4-b]-1,3,4-thia-
diazole (IVl). Yield: 50%. M.p. 139–140 C (CH3OH), 1H
NMR (CDCl3) d 7.29 (s, 1H), 7.13 (s, 1H), 6.99 (s, 1H), 6.95
(d, J= 8.2 Hz, 1H), 6.90 (dd, J= 8.3, 2.0 Hz, 1H), 4.70 (s,
2H), 4.35 (s, 2H), 3.84 (s, 3H), 3.77 (s, 3H), 3.75 (s, 3H),
3.73 (s, 3H), 2.58 (s, 6H), I.R. v cm1 1602 (C‚N), 1555,
1516, 1462 (C‚C), 1266 (NAN‚C), 1336 (SAO antisym.),
1139 (SAO sym.), Analysis: C23H27N5O6S2 (533). Calc.%:
C:51.78, H:5.06, N:13.13. Found%: C:51.81, H:5.10, N:13.15.ity of novel 3,6-disubstituted 1,2,4-triazolo-[3,4-b]-1,3, 4-thiadiazole derivatives.
Synthesis and anticancer activity 52.1.2.13. 3-[2-(N,N-dimethylsulfamoyl)-4,5-dimethoxy-ben-
zyl]-6-phenoxymethyl-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole
(IVm). Yield: 41%. M.p. 178–179 C (CH3OHACH2Cl2), 1H
NMR (CDCl3) d 7.37–7.31 (m, 2H), 7.29 (s, 1H), 7.13 (s, 1H),
7.09 (d, J= 7.7, 1.0 Hz, 2H), 7.06–7.01 (m, 1H), 5.55 (s, 2H),
4.72 (s, 2H), 3.84 (s, 3H), 3.78 (s, 3H), 2.58 (s, 6H), I.R. v cm1
1598 (C‚N), 1572, 1516, 1479 (C‚C), 1267 (NAN‚C), 1337
(SAO antisym.), 1139 (SAO sym.), Analysis: C21H23N5O5S2
(489). Calc.%: C:51.53, H:4.70, N:14.31. Found%: C:51.51,
H:4.67, N:14.33.
2.1.2.14. 3-[2-(N,N-dimethylsulfamoyl)-4,5-dimethoxy-ben-
zyl]-6-cinnamyl-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole (IVn).
Yield: 44%. M.p. 191–193 C (CH3OHACH2Cl2); 1H NMR
(CDCl3) d 7.81 (d, J= 7.1 Hz, 2H), 7.64 (d, J= 16.4 Hz,
1H), 7.60 (d, J= 16.3 Hz, 1H), 7.52–7.40 (m, 3H), 7.30 (s,
1H), 7.16 (s, 1H), 4.73 (s, 2H), 3.84 (s, 3H), 3.80 (s, 3H),
2.62 (s, 6H), I.R. v cm1 1630 (CH‚CH), 1600 (C‚N),
1575, 1576, 1475 (C‚C), 1267 (NAN‚C), 1332 (SAO anti-
sym.), 1138 (SAO sym.), Analysis: C22H23N5O4S2 (485).
Calc.%: C:54.43, H:4.74, N:14.43. Found%: C:54.45, H:4.71,
N:14.39.
2.1.2.15. 3-[2-(N,N-dimethylsulfamoyl)-4,5-dimethoxy-ben-
zyl]-6-[2-(2-methoxy-phenyl)ethyl]-1,2,4-triazolo[3,4-b]-
1,3,4-thiadiazole (IVo). Yield: 37%. M.p. 154–155 C (CH3-
OHACH2Cl2),
1H NMR (CDCl3) d 7.29 (s, 1H), 7.21 (m,
1H), 7.17 (d, J= 7.5 Hz, 1H), 7.10 (s, 1H), 6.95 (d,
J= 8.2 Hz, 1H), 6.84 (t, J= 7.26 Hz, 1H), 4.67 (s, 2H), 3.84
(s, 3H), 3.77 (s, 3H), 3.75 (s, 3H), 3.29 (m, 2H), 3.01 (t,
J= 7.5 Hz, 4H), 2,56 (s, 6H), I.R. v cm1 1601 (C‚N),
1569, 1519, 1477 (C‚C), 1267 (NAN‚C), 1336 (SAO anti-
sym.), 1139 (SAO sym.), Analysis: C23H27N5O5S2 (517).
Calc.%: C:53.38, H:5.22, N:13.53. Found%: C:53.41, H:5.19,
N:13.56.
2.1.2.16. 3-[2-(N,N-dimethylsulfamoyl)-4,5-dimethoxy-ben-
zyl]-6-[2-(4-methoxy-phenyl)ethyl]-1,2,4-triazolo[3,4-b]-
1,3,4-thiadiazole (IVp). Yield: 41%. M.p. 151–152 C (CH3-
OHACH2Cl2),
1H NMR (CDCl3) d 7.29 (s, 1H), 7.18 (d,
J= 8.3 Hz, 2H), 7.11 (s, 1H), 6.83 (d, J= 8.1 Hz, 2H), 4.67
(s, 2H), 3.83 (s, 3H), 3.77 (s, 3H), 3.71 (s, 3H), 2.99 (t,
J= 7.6 Hz, 2H), 2.55 (s, 6H), I.R. v cm1 1601 (C‚N),
1569, 1519, 1477 (C‚C), 1267 (NAN‚C), 1336 (SAO anti-
sym.), 1139 (SAO sym.), Analysis: C23H27N5O5S2 (517).
Calc.%: C:53.38, H:5.22, N:13.53. Found%: C: 53.35,
H:5.24, N:13.50.
2.1.2.17. 3-[2-(N,N-dimethylsulfamoyl)-4,5-dimethoxy-ben-
zyl]-6-(3-phenylpropyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole
(IVq). Yield: 14%. M.p. 128–129 C (CH3OH), 1H NMR
(CDCl3) d 7.30–7.26 (m, 3H), 7.23–7.17 (m, 3H), 7.12 (s,
1H), 4.69 (s, 2H), 3.82 (s, 3H), 3.77 (s, 3H), 3.04 (t,
J= 7.4 Hz, 2H), 2.68 (t, J= 7.7 Hz, 2H), 2.59 (s, 6H), 2.03
(p, J= 7.6 Hz, 2H), I.R. v cm1 1600 (C‚N), 1574, 1516,
1478 (C‚C), 1267 (NAN‚C), 1334 (SAO antisym.), 1139
(SAO sym.), Analysis: C23H27N5O4S2 (501). Calc.%:
C:55.09, H:5.38, N:13.97. Found%: C:55.11, H:5.41, N:14.01.
2.1.2.18. 3-[2-(N,N-dimethylsulfamoyl)-4,5-dimethoxy-ben-
zyl]-6-(2-pyridinyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole
(IVr). Yield: 32%. M.p. 198–199 C (CH3OH), 1H NMRPlease cite this article in press as: Charitos, G. et al., Synthesis and anticancer activi
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7.37–7.15 (m, 2H), 4.79 (s, 2H), 3.83 (s, 3H), 3.78 (s, 3H),
2.62 (s, 6H), I.R. v cm1 1599 (C‚N), 1576, 1517, 1456
(C‚C), 1270 (NAN‚C), 1335 (SAO antisym.), 1137 (SAO
sym.), Analysis: C19H20N6O4S2 (460). Calc.%: C:49.56,
H:4.34, N:18.26. Found%: C:49.60, H:4.31, N:18.30.
2.1.2.19. 3-[2-(N,N-dimethylsulfamoyl)-4,5-dimethoxy-ben-
zyl]-6-(4-pyridinyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole
(IVs). Yield: 37%. M.p. 231–232 C (C2H5OH), 1H NMR
(CDCl3) d 8.85 (d, J= 5.0 Hz, 2H), 7.91 (d, J= 5.0 Hz,
2H), 7.30 (s, 1H), 7.21 (s, 1H), 4.80 (s, 2H), 3.84 (s, 3H),
3.80 (s, 3H), 2.63 (s, 6H), I.R. v cm1 1600 (C‚N), 1561,
1507, 1473, 1411 (C‚C), 1274 (NAN‚C), 1337 (SAO anti-
sym.), 1138 (SAO sym.), Analysis: C19H20N6O4S2 (460).
Calc.%: C:49.56, H:4.34, N:18.26. Found%: C:49.58, H:4.37,
N:18.23.
2.1.2.20. 3-[2-(N,N-dimethylsulfamoyl)-4,5-dimethoxy-ben-
zyl]-6-(3-bromo-5-pyridinyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadi-
azole (IVt). M.p. 227–228 C (C2H5OH), 1H NMR (CDCl3) d
9.10 (d, J= 2.0 Hz, 1H), 8.98 (d, J= 2.2 Hz, 1H), 8.58 (s,
1H), 7.30 (s, 1H), 7.22 (s, 1H), 4.79 (s, 2H), 3.84 (s, 3H),
3.80 (s, 3H), 2.63 (s, 6H), I.R. v cm1 1600 (C‚N), 1573,
1516, 1481, 1440, 1412 (C‚C), 1270 (NAN‚C), 1338 (SAO
antisym.), 1140 (SAO sym.), Analysis: C19H19BrN6O4S2
(539). Calc.%: C:42.30, H:3.52, N:15.58. Found%: C:42.32,
H:3.49, N:15.56.
2.2. Biological evaluation
2.2.1. In vitro anticancer activity
Twenty disubstituted triazolo-thiadiazole derivatives (Scheme 1
and Table 1) were tested for anticancer activity against nine
well established human cancer cell lines (4 ovarian, 2 breast,
1 prostate cancer, 1 epidermoid carcinoma and 1 leukemia)
(Table 2). SKOV-3, OVCAR-3, UWB1.289, UWB1.289
+BRCA1 ovarian cancer cells, MCF7, T-47D breast adeno-
carcinoma cells, PC-3 prostate adenocarcinoma cells, A-431
epidermoid carcinoma cells and MOLT-4 T-lymphoblastic leu-
kemia cells were treated for testing cytostatic (growth inhibi-
tion: IG50, TGI) and cytotoxic/cytocidal (IC50) activity
generated by the newly synthesized compounds at concentra-
tions of 1–100 lM. The cell lines were obtained from the
American Type Culture Collection (ATCC) and were grown
in different culture media according to the instructions. The
MTT ((3-(4,5-imethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay is a well-established and standard method for
evaluating the cytostatic and cytotoxic activity of drugs and
chemicals (Camoutsis et al., 2005; Trafalis et al., 2005, 2004,
2006). Briefly, the cells were plated in 96-well plate at a density
of 3  104 cells/ml per well and maintained for 72 h at 37 C in
a 5% CO2 incubator and grown as monolayers or suspensions.
After 24 h, cells were treated with 1–100 lmol/l of the com-
pounds for 48 h. The viability of cultured cells was estimated
MTT (Sigma, St Louis, Missouri, USA) metabolic assay as
described previously. Absorbance of the converted dye was
measured at a wavelength of 540 nm on an ELISA reader (Ver-
samax, Orleans, USA). The mean concentrations of each drug
that generated 50% or total (100%) growth inhibition (GI50
and TGI, respectively) as well as the drug concentrations thatty of novel 3,6-disubstituted 1,2,4-triazolo-[3,4-b]-1,3, 4-thiadiazole derivatives.
Table 2 Description of histotypes and characteristics of the 8 human cell lines treated with the tested for antineoplastic activity newly
synthesized triazolo-thiadiazole derivatives.
Cancer type Human cell line
designation
Oncogenes Special characteristics
Ovarian
adenocarcinoma
SKOV-3 Tumor Necrosis Factor; Diphtheria Toxin; Cis-platinum and Adriamycin
resistant
Epithelial ovarian
adenocarcinoma
OVCAR-3 Androgen/Estrogen/Progesterone receptor positive;
Adriamycin, Melphalan and Cisplatin resistant
Ovarian carcinoma UWB1.289 p53+
BRCA1 –
(mutated)
Estrogen/Progesterone receptor negative/BRCA1 mutated
Ovarian carcinoma UWB1.289
+BRCA1
p53+
BRCA1+
Estrogen/Progesterone receptor negative
Epithelial breast
adenocarcinoma
MCF7 WNT7B+ Estrogen receptor positive
Insulin-like growth factor binding proteins (IGFBP) BP-2; BP-4; BP-5
Epithelial breast
adenocarcinoma
T-47D WNT7B+ Calcitonin; androgen receptor, positive; progesterone receptor, positive;
glucocorticoid; prolactin; estrogen receptor, positive
Prostate
Adenocarcinoma
PC-3 Hormone resistant
Acute T-
lymphoblastic
leukemia
MOLT-4 Terminal deoxynucleotidyl transferase (TdT) expressed
Epidermoid
carcinoma
A-431 P53 High expression of the Epidermal growth factor receptor (EGFR)
6 G. Charitos et al.produced cytotoxicity against 50% of the cultured cells [(half
maximal cytotoxic concentration (IC50)] were calculated using
the linear regression method. Using seven absorbance mea-
surements [time 24 h (Ct24), control growth 72 h (Ct72), and
test growth in the presence of drug at five concentration levels
(Tt72x)], the percentage of growth was calculated at each level
of the drug concentrations. The percentage growth inhibition
was calculated according to National Cancer Institute (NCI)
as follows: [(Tt72x)-(Ct24)/(Ct72)-(Ct24)]  100 for concentra-
tions for which Tt72x > Ct24 and [(Tt72x)-(Ct24)/Ct24]  100
for concentrations for which Tt72x < Ct24; GI50 was calcu-
lated from [(Tt72x)-(Ct24)/(Ct72)-(Ct24)]  100 = 50,TGI
from [(Tt72x)-(Ct24)/(Ct72)-(Ct24)]  100 = 0, and IC50
from [(Tt72x)-(Ct24)/Ct24]  100 = 50. All the experiments
were carried out in triplicate.
2.2.2. In vivo acute toxicity
For intraperitoneal (i.p.) treatment, stock solutions of the 20
tested compounds (Scheme 1 and Table 1) were prepared
immediately before use. They were suspended in corn oil in
the desired concentration following initial dissolution in 10%
dimethylsulfoxide (DMSO). This concentration by itself pro-
duced no observable toxic effect.
C57Bl/6 female mice were used for toxicity studies. Mice
were obtained from experimental section of the Hellenic Pas-
teur Institute.
Briefly, the acute toxicity induced by the tested compounds
was determined, as previously had very well described (Trafalis
et al., 2005, 2004, 2006) following a single i.p. injection into
groups of ten (10) C57Bl/6 mice at four different dosages; the
mice were observed for 30 days and the therapeutic dose of
the compounds, which is usually defined as LD10 (lethal dose
for 10% of animals) as well as LD50 (lethal dose for 50% of
animals) was determined after graphical estimation (30-dayPlease cite this article in press as: Charitos, G. et al., Synthesis and anticancer activ
Arabian Journal of Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.09.015curves). The toxicity of the tested compounds was assessed
from lethality in C57Bl/6 mice. The LD50 and LD10 values
were estimated graphically, where the percentage of deaths
due to the toxicity of each dose was shown in the ordinate,
while the administered doses were indicated on the abscissa.
2.3. In silico studies
PharmMapper Server was used to obtain information regard-
ing possible mechanisms behind the activity of studied com-
pounds (Chen et al., 2011; Liu et al., 2010). PharmMapper
Server is a freely accessed web-server designed to identify
potential target candidates for the given probe small molecules
(drugs, natural products, or other newly discovered com-
pounds with binding targets unidentified). PharmMapper uti-
lizes an integrated pharmacophore matching platform with
statistical method for potential target identification (http://
59.78.96.61/pharmmapper/index.php). Compounds are scored
according to their fitness on the pharmacophore models.
Moreover, the program encompasses z0 score which is a score
generated from the molecule’s fit score and a library score
matrix calculated beforehand. It combines the fit score and
its corresponding vector in the score matrix together and nor-
malizes it to a vector with a mean of zero and a standard devi-
ation of one. Compared to the fit score z0-score not only
applies the pharmacophore matching method but also consid-
ers statistic factors lying behind. Generally, large positive z0-
score indicates high significance of the target to a query com-
pound, as well large negative z0-score indicates that the target
may not be significant enough.
LigandScout 4.0 Advanced (Wolber and Langer, 2005) was
utilized to create the shared pharmacophore features of the
active compounds IVn and IVb as well as those of the inactive
ones, IVe and IVa. LigandScout 4.0 Advanced is availableity of novel 3,6-disubstituted 1,2,4-triazolo-[3,4-b]-1,3, 4-thiadiazole derivatives.
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teligand.com/ligandscout.
3. Results and discussion
3.1. In vitro cytostatic and cytotoxic activity
The 20 novel triazolo-thiadiazole derivatives (Scheme 1 and
Table 1) were tested in vitro against a panel of 9 well-
established human cancer cell lines (Table 2). Results regard-
ing the most active derivatives are presented in Table 3a. As
it is shown, compounds IVn and IVb exhibited a very potent
cytostatic and cytotoxic effect against all tested cell lines.
The derivatives IVi and IVk were active but exhibited lower
anticancer potency, while the compounds IVr and IVa were
less active. The derivatives IVe and IVc were relatively inactive
at the concentrations tested in vitro. Although the triazolo-
thiadiazole derivatives IVn and IVb produced important cyto-
toxic activity, in general it was demonstrated that the tested
derivatives rather hold a potential cytostatic than cytotoxic
anticancer activity, probably acting like antimetabolites or tar-
geted molecular pathway agents (Tonkinson et al., 1997;
Svendsrud et al., 1997). The rest 12 triazolo-thiadiazole deriva-
tives (IVa, IVd, IVf, IVg, IVh, IVj, IVl, IVm, IVo, IVp, IVq,
and IVs) were inactive at the concentrations tested with
IG50, TGI and IC50 > 100 lM in all 9 human cancer lines.
For comparison reasons, three well-established anticancer
agents currently used in cancer chemotherapy were tested for
cytostatic and cytotoxic effects in vitro, against 6 human cancer
cell lines (2 ovarian, 1 prostate, 2 breast cancer and 1 leukemia)Table 3a Growth inhibition/cytostatic (GI50 and TGI) and cytoc
synthesized triazolo-thiadiazole derivatives on nine human cancer ce
Compound GI50
(lM)
TGI
(lM)
IC50
(lM)
UWB1.289 + BRCA1 IVn 12 28 42 OVCA
IVb 8 64 >100
IVi 8 64 >100
IVk 16 >100 >100
IVr >100 >100 >100
IVa 76 >100 >100
IVe 90 >100 >100
IVc 85 >100 >100
UWB1.289 IVn 12 56 >100 MCF-7
IVb 30 50 >100
IVi 13 >100 >100
IVk 30 >100 >100
IVr >100 >100 >100
IVa 56 >100 >100
IVe >100 >100 >100
IVc >100 >100 >100
PC-3 IVn 12 31 85 MOLT
IVb 20 45 >100
IVi 27 >100 >100
IVk 44 >100 >100
IVr >100 >100 >100
IVa 62 >100 >100
IVe >100 >100 >100
IVc >100 >100 >100
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platin newer agent that exerts its antineoplastic effects acting
like a non-classical alkylator interacting with DNA.
Vinorelbine is a very active antitumor agent, the first 50NOR
semi-synthetic vinca alkaloid, pharmacologically acting due
to inhibition of mitosis through interaction with tubulin.
Pemetrexed is an evolved newer agent chemically similar to
folic acid, in the class of chemotherapy drugs called folate
antimetabolites, producing its effects by inhibiting three
enzymes used in purine and pyrimidine synthesis: thymidylate
synthase, dihydrofolate reductase, and glycinamide ribonu-
cleotide formyltransferase. Thus, by inhibiting the formation
of precursor purine and pyrimidine nucleotides, pemetrexed
prevents the formation of DNA and RNA which are required
for the growth and survival of cancer cells.
It is notable that all the compounds produced relatively
very low acute toxicity on C57Bl/6 mice (Table 4). All
LD10s from the i.p. administration of the tested triazolo-
thiadiazole derivatives were over 350 mg/kg whereas LD50 s
were not reached in any case. For the derivatives IVa, IVc-h,
IVj-m, and IVo-s, acute toxicity was not demonstrated at the
higher of the i.p. administrated dosage and LD10 s and
LD50 s were not reached (>500 mg/kg).
Thus, the new triazolo-thiadiazole derivatives that were
tested and specifically IVn, IVb, IVi, IVk, IVr and IVa gener-
ated potent cytostatic and cytotoxic effects against all tested
human cancer cell lines in vitro and better or equal activity
in comparison with three well-established antitumor drugs in
current cancer chemotherapy. This is important activity comes
together with the generation of relatively very low acuteidal/cytotoxic (IC50) anticancer effects induced by the 8 newly
ll lines.
GI50
(lM)
TGI
(lM)
IC50
(lM)
GI50
(lM)
TGI
(lM)
IC50
(lM)
R-3 5 12 25 SKOV-3 8 16 32
3 32 >100 8 38 >100
8 68 >100 12 56 >100
5 86 >100 6 >100 >100
24 >100 >100 20 >100 >100
65 >100 >100 80 >100 >100
97 >100 >100 >100 >100 >100
95 >100 >100 >100 >100 >100
15 45 >100 T-47D 8 37 >100
22 50 >100 27 55 >100
18 >100 >100 24 >100 >100
40 >100 >100 28 >100 >100
>100 >100 >100 >100 >100 >100
65 >100 >100 52 >100 >100
>100 >100 >100 >100 >100 >100
>100 >100 >100 >100 >100 >100
-4 4 21 36 A-431 11 28 78
6 45 78 16 36 >100
7 55 >100 19 75 >100
10 >100 >100 35 >100 >100
85 >100 >100 >100 >100 >100
42 >100 >100 74 >100 >100
55 >100 >100 >100 >100 >100
94 >100 >100 >100 >100 >100
ty of novel 3,6-disubstituted 1,2,4-triazolo-[3,4-b]-1,3, 4-thiadiazole derivatives.
Table 3b Growth inhibition/cytostatic (GI50 and TGI) and cytocidal/cytotoxic (IC50) anticancer effects induced by 3 well-established
cancer therapeutics anticancer agents.
Human cancer cell lines Anticancer agents
Carboplatin Pemetrexed Vinorelbine
IG50 (lM) TGI (lM) IC50 (lM) IG50 (lM) TGI (lM) IC50 (lM) IG50 (lM) TGI (lM) IC50 (lM)
OVCAR-3 66 >100 >100 >100 >100 >100 <1 <1 70
SCOV-3 >100 >100 >100 >100 >100 >100 <1 3 79
PC-3 >100 >100 >100 >100 >100 >100 <1 28 87
MCF-7 >100 >100 >100 <1 >100 >100 <1 21 65
T-47D >100 >100 >100 >100 >100 >100 <1 52 >100
MOLT-4 74 >100 >100 <1 >100 >100 <1 5 >100
Table 4 Acute toxicity of the compounds in C57Bl/6. The
acute toxicity induced by the tested compounds following a
single intraperitoneal (i.p.) injection into groups of ten (10)
C57Bl/6 mice at four different dosages was determined; LD50
and LD10 = lethal doses for 50% and 10% of the population
of the treated mice. Where LD50 s and LD10 s were not
reached it is indicated as over 500 mg/kg (>500), the higher
dosage that was administered.
Compounds LD50 (mg/kg) LD10 (mg/kg)
IVn 375 >500
IVb 430 >500
IVi 480 >500
IVk >500 >500
IVr >500 >500
IVa >500 >500
IVe >500 >500
IVc >500 >500
8 G. Charitos et al.toxicity on C57Bl/6 mice in vivo, lending a significant clinical
practice accrued therapeutic ratio.
These results provide evidence that the newly synthesized
compounds, especially IVn and IVb are of high interest for
cancer therapeutics, since they provide very low acute toxicity
and conclusively low systemic toxicity in correlation with high
anticancer activity in vitro thus relatively high therapeutic
ratios.
3.2. Proposed mechanisms behind activity
Triazolo-thiadiazole derivatives exhibit antitumor activity by
targeting and inhibiting various molecular pathways and cru-
cial macromolecules in cancer cells. Molecular targets and
pathways involved in the biological activities of these com-
pounds are protein kinases (tyrosine, serine and threonine
kinases), phosphatidylinositol-3 lipid kinases, metallopro-
teinases, cells defective in the von Hippel-Lindau gene, Bcl-2
family proteins, histone acetyltransferases and deacetylases
and cancer cells with high expression in Cancer 1 (Hec1)
(Leoni et al., 2014a, 2014b; Morigi et al., 2015).
Implementation of PharmMapper on two active (IVb and
IVn) versus two inactive (Iva and IVe) compounds has resulted
in several significant and insignificant protein targets which are
presented in Table 5. These target proteins may partiallyPlease cite this article in press as: Charitos, G. et al., Synthesis and anticancer activ
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IVb on ovarian and epithelial ovarian carcinoma and adeno-
carcinoma cell lines (Table 3). As can be observed, apoptotic
protease-activating factor 1 (APAF1) has been matched as
the most significant target for IVn (z0 score equal to 3.81),
and it is estimated to be significant for IVb (z0 score equal to
2.40) but rather insignificant for the activity of IVa (z0 score
equal to 0.80) and IVe (z0 score equal to 1.26). Indeed, the reg-
ulation of APAF-1 activity is suggested to be important for
apoptosis in some ovarian cancers (Wolf et al., 2001). Further-
more, in ovarian carcinoma, the APAF1 gene has been found
to be active (Wolf et al., 2001). APAF-1 is the structural core
of the apoptosome. Oligomeric APAF-1 mediates the cyto-
chrome c-dependent autocatalytic activation of pro-caspase-9
(Apaf-3), leading to the activation of caspase-3 and apoptosis.
A second common significant protein target for IVn (z0
score equal to 3.13) and IVb (z0 score equal to 2.73) and
insignificant for IVa (z0 score equal to 0.47) and IVe (z0 score
equal to -0.05) is the Tyrosine-protein kinase HCK. Tyrosine
kinase plays an essential role for the selection and maturation
of developing T-cell and in mature T-cell function. It is consti-
tutively associated with the cytoplasmic portions of the CD4
and CD8 surface receptors. Tyrosine-protein kinase has been
correlated with leukemia.
The cell division protein kinase 2 (CDK2), another possible
target for IVb (z0 score equal to 2.89), is hyperactivated and
most often associated with amplification and/or overexpres-
sion of its partner cyclins A and E, particularly in breast can-
cer, ovarian and endometrial carcinomas, lung and thyroid
carcinoma, melanoma and osteosarcoma (Peyressatre et al.,
2015).
Compound IVb displays also significant z0 score (2.46) for
the matrix metalloproteinase 3 (MMP3) which along with
MMP2 and MMP9 is representative protease known to be
involved in ovarian metastasis (Wu et al., 2014).
Heat shock protein HSP 90 is a possible target especially
for IVn (z0 score equal to 2.75). The suppression of HSP90 sig-
nals the inhibition of multi-receptor tyrosine kinases (RTKs)
and results in profound pro-apoptotic and anti-proliferative
effects in individual ovarian cancer cell lines and primary
tumors (Jiao et al., 2011).
Finally, lymphocyte-specific protein tyrosine kinase Lck,
which belongs to the Proto-oncogene tyrosine-protein kinase
(Src) family, has been found significant target for IVn (z0 score
equal to 2.37 versus 0.46, 0.53 and 0.51 for IVb, IVa and IVe
respectively), and may explain its activity on Acuteity of novel 3,6-disubstituted 1,2,4-triazolo-[3,4-b]-1,3, 4-thiadiazole derivatives.
Table 5 Results from PharmMapper matching platform indicating potential protein target candidates.
Target protein Compound
z0 scores
IVn IVb IVa IVe
Cell division protein kinase 2
P24941
PDB:1DI8
0.02 2.89 2.58 2.56
Stromelysin-1
MMP3 HUMAN
PDB: 1CIZ
0.49 2.46 0.11 0.53
Apoptotic protease-activating factor 1 APAF HUMAN
PDB: 1Z6T
3.81 2.40 0.80 1.26
Tyrosine-protein kinase HCK
HCK HUMAN
PDB: 1QCF
3.13 2.73 0.47 -0.05
Heat shock protein HSP 90-alpha
HS90A HUMAN
PDB: 1UYG
2.75 1.12 2.02 2.30
Proto-oncogene tyrosine-protein kinase LCK
LCK HUMAN
PDB: 1QPC
2.37 0.46 0.53 0.51
High significance values appear in bold.
Figure 1 (left) Shared pharmacophore features of the overlaid active molecules IVn (light blue) and IVb (purple) include six hydrogen
bond acceptors (red spheres), three aromatic rings (blue rings) and three hydrophopic regions (yellow spheres); (right) shared
pharmacophore features of the overlaid inactive molecules IVe (light green) and IVa (pink) including six hydrogen bond acceptors (red
spheres), four aromatic rings (blue rings) and two hydrophopic regions (yellow spheres). (For interpretation of the references to color in
this figure legend, the reader is referred to the web version of this article.)
Synthesis and anticancer activity 9T-lymphoblastic leukemia cell lines (Table 3). Lck phosphory-
lates specific tyrosine residues in other proteins involved in the
intracellular signaling pathways of lymphocytes. Upregulation
of Lck is observed in lymphoma, breast and colon cancer (Patil
and Kundu, 2005).
In an effort to further explore structure-activity relation-
ship features, two active (IVb and IVn) and two inactive
(IVa and IVe) analogues have been selected and subjected to
ligand based pharmacophore model generation (Fig. 1).
Results indicate that the shared pharmacophore model of the
active compounds is characterized by one more hydrophobic
feature which might contribute positively to their binding at
a hydrophobic core of the biological target.Please cite this article in press as: Charitos, G. et al., Synthesis and anticancer activi
Arabian Journal of Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.09.0154. Conclusions
The role of the thiadiazole and triazole heterocycles as a versatile scaf-
fold for the synthesis of new derivatives has been presented. Some of
the newly synthesized 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole deriva-
tives and more specifically IVn and IVb showed substantial cytostatic
and cytotoxic antineoplastic activity in vitro and they produced rela-
tively low acute toxicities in vivo. Apoptotic protease-activating factor
1 (APAF1), tyrosine-protein kinase HCK, cell division protein kinase 2
(CDK2) and matrix metalloproteinase 3 (MMP3) may be involved in
the biological activities of active analogues on ovarian and epithelial
ovarian carcinoma and adenocarcinoma cell lines. Moreover, the
lymphocyte-specific protein tyrosine kinase Lck may explain the activ-
ity of IVn on Acute T-lymphoblastic leukemia cell lines.ty of novel 3,6-disubstituted 1,2,4-triazolo-[3,4-b]-1,3, 4-thiadiazole derivatives.
10 G. Charitos et al.Conclusively, many of these derivatives might be useful to increase
the effects of standard drugs and improve the therapeutic response in
cancer patients.
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